MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy

Go here to read the rest:
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders